Blueprint Medicines Corporation
BPMC
Rang in Aktien
#2365
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Aktienkurs
$129.46
Zuletzt synchronisiert: 2025-07-18
Marktkapitalisierung
$8.36B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Blueprint Medicines Corporation (BPMC)
Kategorie
Healthcare
Umsatz von Blueprint Medicines Corporation (BPMC)
Umsatz im Mar 2025 TTM: $562.12M
Laut den aktuellen Finanzberichten von Blueprint Medicines Corporation beträgt der derzeitige Umsatz des Unternehmens (TTM) $562.12M. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $249.38M eine Steigerung gegenüber dem Umsatz im Jahr 2022, der $204.04M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Blueprint Medicines Corporation von 2013 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $562.12M | 10.47% |
| 2024 | $508.82M | 104.04% |
| 2023 | $249.38M | 22.22% |
| 2022 | $204.04M | 13.30% |
| 2021 | $180.08M | -77.31% |
| 2020 | $793.74M | 1,093.37% |
| 2019 | $66.51M | 49.39% |
| 2018 | $44.52M | 107.79% |
| 2017 | $21.43M | -22.85% |
| 2016 | $27.77M | 143.61% |
| 2015 | $11.40M | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 2,145.84% |
US
|
|
| $2.23B | 296.36% |
US
|
|
| $15.74B | 2,700.88% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 971.17% |
NL
|
